References
- Shulman NB, Martinez B, Brogan D, Carr AA, Miles C G. Financial costs as an obstacle to hypertension therapy. American Journal of Public Health 1986; 76: 1105–1103
- Drummond MF, Ward G H. The financial burden of stroke and the economic evaluation of treatment alternatives. Stroke, epidemiological, therapeutic and socio-economic aspects, FC Rose. Royal Society of Medicine, London 1986; 147–162
- Weinstein MD, Stason W B. Hypertension: a policy perspective. Harvard University Press, Cambridge 1976
- Kawachi I, Malcolm L A. The cost-effectiveness of treating mild to moderate hypertension: a reappraisal. Journal of Hypertension 1991; 9: 199–208
- Edelson JT, Weinstein MC, Tosteson AN, Williams L, Lee TH, et al. Long term cost effectiveness of various initial monotherapies for mild to moderate hypertension. Journal of the American Medical Association 1990; 263: 407–413
- Fletcher AE, Chester PC, Hawkins C MA, et al. The effects of verapamil and propranolol on quality of life in hypertension. J Hum Hypertension 1989; 3: 125–130
- Bulpitt CJ. Quality of life in hypertensive patients. Hypertensive cardiovascular disease pathophysiology and treatment, A Amery, R Fagard, P Lijnen, J Staessen. Martinus Nijhoff, The Hague 1982; 929–948
- Fanshel S, Bush J W. A health status index and its application to health services outcomes. Operations Res 1970; 18: 1020–1066
- Fletcher A. Pressure to treat and pressure to cost: a review of cost-effectiveness analysis. J Hypertension 1991; 9: 193–198
- Johannesson M, Jönsson B. A review of cost-effectiveness analyses of hypertension treatment. PharmacoEconomics 1992; 1(4)250–264
- Weinstein MC, Stason W B. Allocation of resources to manage hypertension. New England Journal of Medicine 1977; 296: 732–739
- Nissinen A, Tuomilehto J, Kottke TE, Puska P. Cost-effectiveness of the North Karelia hypertension program 1972–1977. Medical Care 1986; 24: 767–780
- Littenberg B, Garber AM, Sox H C. Screening for hypertension. Annals of Internal Medicine 1990; 112: 192–202
- Kawachi I, Malcolm L A. The cost-effectiveness of treating mild-to-moderate hypertension: a reappraisal. Journal of Hypertension 1991; 9: 199–208
- Johannesson M, Jönsson B. Cost-effectiveness analysis of hypertension treatment: a review of methodological issues. Health Policy 1991; 19: 55–78
- Lindgren B, Persson U. the cost-effectiveness of a new anti-hypertensive drug, doxazosin. Current Therapeutic Research 1989; 45: 738–760
- Bulpitt CJ, Fletcher A E. Measuring costs and financial benefits in randomized controlled trials. Amer Heart J 1990; 119: 766–771
- Johannesson M, Fagerberg B. A health-economic comparison of diet and drug treatment in obese men with mild hypertension. Journal of Hypertension 1992; 10: 1063–1070
- Johannesson M, Wikstrand J, Jönsson B, Berglund G, Tuomilehto J. Cost-effectiveness of antihypertensive treatment. Metoprolol versus thiazide diuretics. PharmacoEconomics 1993; 3: 36–44
- Mac Mahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al. Blood pressure, stroke, and coronary heart disease, Part 1: Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765–774
- Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, et al. Blood pressure, stroke, and coronary heart disease, Part 2: Short term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 837–838
- Wikstrand J, Warnold I, Olsson G, Tuomilehto J, Elmfeldt D, et al. Primary prevention with metoprolol in patients with hypertension. Mortality results of the MAPHY study. Journal of the American Medical Association 1988; 259: 1976–1982
- Wilhelmsen L, Berglund G, Elmfeld D, Fitzsimons T, Holzgreve H, Hosie J, Hörnkvist P-E, Pennert K, Tuomilehto J, Wedel H. (on behalf of the Heart Attack Primary Prevention in Hypertension Trial Research Group). Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY Trial. J. Hypertension 1987; 5: 561–572